Synthetic farnesoid X receptor (FXR) agonists: A new class of cholesterol synthesis inhibitors and antiproliferative drugs

Drugs of the Future

Volumn 24, Issue 4, 1999, Pages 431-438

  Niesor, Eric J ^a   Flach, Jean ^a   Weinberger, Cary ^b   Bentzen, Craig L ^a  

^a Symphar SA   (Switzerland)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1 BISPHOSPHONIC ACID ESTER DERIVATIVE; 2 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL) 1,1 ETHANEBISPHOSPHONIC ACID TETRAISOPROPYL ESTER; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARBON 14; CELL NUCLEUS RECEPTOR; CHOLESTEROL; CHOLESTEROL DERIVATIVE; FARNESAL; FARNESOID X RECEPTOR; FARNESOID X RECEPTOR AGONIST; FARNESOL; FARNESYL ACETATE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYPOCHOLESTEROLEMIC AGENT; ISOPRENOID; JUVENILE HORMONE; MEVALONIC ACID; NEROLIDOL; PHORBOL 13 ACETATE 12 MYRISTATE; PHYTOHEMAGGLUTININ; PRASTERONE; RETINOID X RECEPTOR; RIP 14; SR 12813; STATIN; TERPENOID; TOCOPHEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CHOLESTEROL SYNTHESIS; CONCENTRATION RESPONSE; HUMAN; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0032996296     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.04.858621     Document Type: Review

References (72)

1. Meier, C.A. Regulation of gene expression by nuclear hormone receptors. J Recept Signal Trans Res 1997, 17: 319-35.
2. Amero, S.A., Kretsinger, R.H., Moncrief, N.D., Yamamoto, K.R., Pearson, W.R. The origin of nuclear receptor proteins: A single precursor distinct from other transcription factors. Mol Endocrinol 1992, 6: 3-7.
3. Enmark, E., Gustafsson, J.A. Orphan nuclear receptors - The first eight years. Mol Endocrinol 1996, 10: 1293-307.
4. Soontjens, C.D., Rafter, J.J., Gustafsson, J.A. Ligands for orphan receptors. J Endocrinol 1996, 150: S241-57.
5. Forman, B.M. Orphan nuclear receptors and their ligands. In: Molecular Biology of Steroid and Nuclear Hormone Receptors. Freedman, L.P. (Ed.). Birkhauser: Boston 1998, 281-305.
6. Lala, D.S., Syka, P.M., Lazarchik, S.B., Mangelsdorf, D.J., Parker, K.L., Heyman, R.A. Activation of the orphan nuclear receptor steroidogenic factor 1 by oxysterols. Proc Natl Acad Sci USA 1997, 94: 4895-900.
7. Forman, B.M., Ruan, B., Chen, J., Schroepfer, G.J., Evans, R.M. The orphan nuclear receptor LXR-α is positively and negatively regulated by distinct products of mevalonate metabolism. Proc Natl Acad Sci USA 1997, 94: 10588-93.
8. Lehmann, J.M., Kliewer, S.A., Moore, L.B. et al. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem 1997, 272: 3137-40.
9. Moore, D.D. Diversity and unity in the nuclear hormone receptors: A terpenoid receptor superfamily. New Biol 1990, 2: 100-5.
10. Sacchettini, J.C., Poulter, C.D. Biochemistry - Creating isoprenoid diversity. Science 1997, 277: 1788-9.
11. Forman, B.M., Chen, J., Evans, R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 1997, 94: 4312-7.
12. Krey, G., Braissant, O., Lhorset, F. et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 1997, 11: 779-91.
13. Issemann, I., Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347: 645-50.
14. Schoonjans, K., Staels, B., Auwerx, J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996, 37: 907-25.
15. Lehmann, J.M., Moore, L.B., Smitholiver, T.A., Wilkison, W.O., Willson, T.M., Kliewer, S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR-γ). J Biol Chem 1995, 270: 12953-6.
16. Forman, B.M., Goode, E., Chen, J. et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995, 81: 687-93.
17. Hanley, K., Jiang, Y., Crumrine, D. et al. Activators of the nuclear hormone receptors PPAR-α and FXR accelerate the development of the fetal epidermal permeability barrier. J Clin Invest 1997, 100: 705-12.
18. Weinberger, C. A model for farnesoid feedback control in the mevalonate pathway. Trends Endocrinol Metab 1996, 7: 1-6.
19. O'Brien, M.L., Rangwala, S.M., Henry, K.W. et al. Convergence of three steroid receptor pathways in the mediation of nongenotoxic hepatocarcinogenesis. Carcinogenesis 1996, 17: 185-90
20. Keller, H., Dreyer, C., Medin, J., Mahfoudi, A., Ozato, K., Wahli, W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA 1993, 90: 2160-4.
21. Seol, W., Choi, H.S., Moore, D.D. Isolation of proteins that interact specifically with the retinoid X receptor - Two novel orphan receptors. Mol Endocrinol 1995, 9: 72-85.
22. Zavacki, A.M., Lehmann, J.M., Seol, W., Willson, T.M., Kliewer, S.A., Moore, D.D. Activation of the orphan receptor RIP 14 by retinoids. Proc Natl Acad Sci USA 1997, 94: 7909-14.
23. Kensler, T.W., Mueller, G.C. Inhibition of mitogenesis in bovine lymphocytes by juvenile hormones. Life Sci 1977, 22: 505-10.
24. Kensler, T.W., Verma, A.K., Boutwell, R.K., Mueller, G.C. Effects of retinoic acid and juvenile hormone on the induction of ornithine decarboxylase activity by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 1978, 38: 2896-9.
25. Suk, W.A., Ceccorulli, L.M., Long, C.W. Juvenile hormones inhibit marine cell cycle progression and expression of type C viruses. In Vitro 1981, 17: 412-20.
26. Harmon, M.A., Scott, T.C., Li, Y., Boehm, M.F., Phillips, M.A., Mangelsdorf, D.J. Trypanosoma brucei - Effects of methoprene and other isoprenoid compounds on procyclic and bloodstream forms in vitro and in mice. Exp Parasitol 1997, 87: 229-36.
27. Vladusic, E.A., Bussmann, L.E., Visconti, P.E. et al. Effects of juvenile hormone on mammalian steroidogenesis. J Steroid Biochem Mol Biol 1994, 50: 181-7.
28. Brown, M.S., Faust, J.R., Goldstein, J.L. Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J Biol Chem 1978, 253: 1121-8.
29. Bradfute, D.L., Simoni, R.D. Non-sterol compounds that regulate cholesterogenesis: Analogues of farnesyl pyrophosphate reduce 3-hydroxy-3-methylglutaryl-coenzyme A reductase levels. J Biol Chem 1994, 269: 6645-50.
30. Correl, C.C., Ng, L., Edwards, P.A. Identification of farnesol as the non-sterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl-coen-zyme A reductase. J Biol Chem 1994, 269: 17390-3.
31. Cenedella, R.J. Posttranscriptional regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in lens epithelial cells by mevalonate-derived nonsterols. Exp Eye Res 1997, 65: 63-72.
32. Cenedella, R.J. Cholesterol and cataracts. Surv Ophthalmol 1996, 40: 320-37.
33. Meigs, T.E., Roseman, D.S., Simoni, R.D. Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo. J Biol Chem 1996, 271: 7916-22.
34. Keller, R.K., Zhao, Z.H., Chambers, C., Ness, G.C. Farnesol is not the nonsterol regulator mediating degradation of HMG-CoA reductase in rat liver. Arch Biochem Biophys 1996, 328: 324-30.
35. Lopez, D., Chambers, C.M., Ness, G.C. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors unmask cryptic regulatory mechanisms. Arch Biochem Biophys 1997, 343: 118-22.
36. Siperstein, M.D. Role of cholesterogenesis and isoprenoid synthesis in DNA replication and cell growth. J Lipid Res 1984, 25: 1462-8.
37. Joly, A., Edwards, P.A. Biological effects of isoprenoids. Curr Opin Lipidol 1991, 2: 283-7.
38. Rao, K.N. The significance of the cholesterol biosynthetic pathway in cell growth and carcinogenesis. Anticancer Res 1995, 15: 309-14.
39. Jakobisiak, M., Bruno, S., Skierski, J.S., Darzynkiewicz, Z. Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA 1991, 88: 3628-32.
40. Perez-Sala, D., Mollinedo, F. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun 1994, 199: 1209-15.
41. Chakrabarti, R., Engleman, E.G. Interrelationships between mevalonate metabolism and the mitogenic signaling pathway in T lymphocyte proliferation. J Biol Chem 1991, 266: 12216-22.
42. Haug, J.S., Goldner, C.M., Yazlovitskaya, E.M., Voziyan, P.A., Melnykovych, G. Directed cell killing (apoptosis) in human lymphoblastoid cells incubated in the presence of farnesol: Effect of phosphatidylcholine. Biochim Biophys Acta 1994, 1223: 133-40.
43. Voziyan, P.A., Haug, J.S., Melnykovych, G. Mechanism of farnesol cytotoxicity - Further evidence for the role of PKC-dependent signal transduction in farnesol-induced apoptotic cell death. Biochem Biophys Res Commun 1995, 212: 479-86.
44. Voziyan, P.A., Goldner, C.M., Melnykovych, G. Farnesol inhibits phosphatidylcholine biosynthesis in cultured cells by decreasing choline phosphotransferase activity. Biochem J 1993, 295: 757-62.
45. Miquel, K., Pradines, A., Favre, G. Farnesol and geranyl-geraniol induce actin cytoskeleton disorganization and apoptosis in A549 lung adenocarcinoma cells. Biochem Biophys Res Commun 1996, 225: 869-76.
46. Adany, I., Yazlovitskaya, E.M., Haug, J.S., Voziyan, P.A., Melnykovych, G. Differences in sensitivity to farnesol toxicity between neoplastically and non-neoplastically derived cells in culture. Cancer Lett 1994, 79: 175-9.
47. Yazlovitskaya, E.M., Melnykovych, G. Selective farnesol toxicity and translocation of protein kinase C in neoplastic HeLa-S3K and non-neoplastic CF-3 cells. Cancer Lett 1995, 88: 179-83.
48. Suckling, K.E., Kerns, W.D., Jackson, B. et al. SK&F 99085/SR-9223i, a novel hypocholesterolemic agent with multiple anti-atherosclerotic properties, lowers plasma cholesterol in normocholesterolemic animals. Atherosclerosis 1994, 109: 166-7.
49. Nguyen, L., Phan, H.T., Azoulay, R. et al. Synthesis and biological activity of a series of novel bisphosphonate esters with hypocholesterolemic and multiple anti-atherosclerotic properties. 13th Int Symp Med Chem (Paris, France) 1994.
50. Berkhout, T.A., Simon, H.M., Jackson, B. et al. SR-12813 lowers plasma cholesterol in beagle dogs by decreasing cholesterol biosynthesis. Atherosclerosis 1997, 133: 203-12.
51. Berkhout, T.A., Simon, H.M., Patel, D.D. et al. The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem 1996, 271: 14376-82.
52. Niesor, E., Gillespie, A., Antoni, I., Villemin, P., Flach, J., Bentzen, C. SR-45023A is a new anticancer agent which inhibits cell proliferation and specifically triggers apoptosis in tumor cells. Proc Am Assoc Cancer Res 1998, 39: 314.
53. Nguyen, L.M., Niesor, E., Phan, H.T., Maechler, P., Bentzen, C.L. Phenol substituted gem-diphosphonate derivatives, process for their preparation and pharmaceutical compositions containing them. US 5043330.
54. Niesor, E., Bentzen, C.L., Nguyen, L.M., Thuillard, J.L., Phan, H.J., Flach, J. Use of phenol substituted diphosphonates as antineoplastic agents. US 9011247.
55. Gross, H., Ozegowski, S. α-Substituierte phosphonate 54. Synthese von 4-hydroxymethanbisphosphonsaüre. Phosphorus Sulfur Silicon 1990, 47: 1-5.
56. Fears, R., Richards, D.H., Ferres, H. The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks. Atherosclerosis 1980, 35: 439-49.
57. Singer, I.I., Kawka, D.W., Kazazis, D.M. et al. Hydroxymethylglutaryl-coenzyme A reductase-containing hepatocytes are distributed periportally in normal and mevinolin-treated rat livers. Proc Natl Acad Sci USA 1984, 81: 5556-60.
58. Berkhout, T.A., Simon, H.M., Niesor, E., Bentzen, C., Suckling, K.E. SK&F 99085/SR-9223i, a novel hypocholesterolemic agent with multiple anti-atherosclerotic properties, suppresses HMG-CoA reductase and induces LDL receptor activity by a novel mechanism. Atherosclerosis 1994, 109: 167.
59. Parker, R.A., Pearce, B.C., Clark, R.W., Gordon, D.A., Wright, J.J.K. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem 1993, 268: 11230-8.
60. Pearce, B.C., Parker, R.A., Deason, M.E. et al. Inhibitors of cholesterol biosynthesis. 2. Hypocholesterolemic and antioxidant activities of benzopyran and tetrahydronaphthalene analogues of the tocotrienols. J Med Chem 1994, 37: 526-41.
61. f-3. Am J Clin Nutr 1991, 53: 1021-6S.
62. Edwards, P.A., Ericsson, J. Signaling molecules derived from the cholesterol biosynthetic pathway: Mechanisms of action and possible roles in human disease. Curr Opin Lipidol 1998, 9: 433-40.
63. Desvergne, B., Wahli, W. PPAR: A key nuclear factor in nutrient/gene interactions? Induc Gene Expr 1995, 1: 142-76.
64. Lemberger, T., Desvergne, B., Wahli, W. Peroxisome proliferator-activated receptors - A nuclear receptor signaling pathway in lipid physiology. Ann Rev Cell Dev Biol 1996, 12: 335-63.
65. Brown, M.S., Goldstein, J.L. Multivalent feedback regulation of HMG-CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 1980, 21: 505-17.
66. Munro, E., Patel, M., Chan, P. et al. Inhibition of human vascular smooth muscle cell proliferation by lovastatin: The role of isoprenoid intermediates of cholesterol synthesis. Eur J Clin Invest 1994, 24: 766-72.
67. Tam, S-P., Brissette, L., Ramharack, R., Deeley, R.G. Differences between the regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and low density lipoprotein receptor in human hepatoma cells and fibroblasts reside primarily at the translational and post-translational levels. J Biol Chem 1991, 266: 16764-73.
68. Cerda, S.R., Wilkinson, J., Broitman, S.A. Regulation of cholesterol synthesis in four colonic adenocarcinoma cell lines. Lipids 1995, 30: 1083-92.
69. Fabricant, M., Broitman, S.A. Evidence for deficiency of low density lipoprotein receptor on human colonic carcinoma cell lines. Cancer Res 1990, 50: 632-6.
70. Bennis, F., Favre, G., Le Gaillard, F., Soula, G. Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549. Int J Cancer 1993, 55: 640-5.
71. Siperstein, M.D., Gyde, A.M., Morris, H.P. Loss of feedback control of hydroxymethylglutaryl coenzyme A reductase in hepatomas. Proc Natl Acad Sci USA 1971, 68: 315-7.
72. He, L., Mo, H., Hadisusilo, S., Qureshi, A.A., Elson, C.E. Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo. J Nutr 1997, 127: 668-74.